japanese%20encephalitis%20virus
JAPANESE ENCEPHALITIS VIRUS

Japanese encephalitis virus is an RNA flavivirus that causes virus encephalitis across Asia, the western Pacific region and parts of Australia.

It is transmitted in an enzootic cycle and the virus is transmitted to humans through the bite of infected Culex tritaeniorhynchus mosquitoes.

There is no specific antiviral treatment for Japanese encephalitis virus and management is mainly symptomatic treatment and supportive care.

Personal protection from mosquito bites in endemic areas and obtaining vaccination are the primary strategies to control Japanese encephalitis virus infection due to lack of specific antiviral therapy, high case fatality, and substantial morbidity.

Japanese%20encephalitis%20virus Treatment

Supportive Therapy

  • Mode of therapy for Japanese encephalitis virus infection are symptomatic treatment, supportive care and management of complications
  • There is no specific antiviral treatment for Japanese encephalitis virus infection
  • Hospitalization for supportive care and close observation is generally required
  • Careful nursing care and physiotherapy are needed to reduce the risk of bed sores, malnutrition and contractures
  • Rest, fluids and pain relievers are used to reduce fever and relieve some symptoms
  • In controlled clinical trials, corticosteroids, Interferon alpha-2a or Ribavirin did not improve clinical outcome
  • Supportive care for Japanese encephalitis patients should be emphasized on:
    • Control of intracranial pressure
    • Maintenance of adequate cerebral perfusion pressure
    • Seizure control
    • Prevention of secondary complications
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Pearl Toh, 12 Jun 2020
A new combination product (AXS-07), which consists of the triptan rizatriptan and the NSAID* meloxicam, led to rapid and sustained pain relief than treatment with either component alone or placebo in patients with a history of inadequate response to prior acute migraine treatment, according to data from the MOMENTUM study released during the AAN 2020 Meeting.
4 days ago
Use of the prescription stimulant methylphenidate appears to also exert a positive effect on the lower urinary tract in children with attention deficit hyperactivity disorder (ADHD) but without voiding dysfunction, specifically increasing voided volume and bladder capacity, as shown in a study.